Translational Research Service
Oncology
Preclinical/TranslationalActive
Key Facts
About Aignostics
Aignostics is a Berlin-based, Charité spin-off founded in 2018, operating at the intersection of AI, digital pathology, and oncology. The company has developed a robust platform centered on proprietary pathology foundation models, which power its products (like the Atlas H&E-TME application) and custom services for biopharma partners. With access to multimodal data from over 30 million patients, deep collaborations with academic institutions like Mayo Clinic, and key industry partnerships (e.g., Bayer), Aignostics is positioned as a leading AI enabler for precision medicine in pathology and drug development. It is a private, likely revenue-generating company providing a mix of platform technology and bespoke analytical services.
View full company profileTherapeutic Areas
Other Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| Bi-XDC with PROTACs | Coherent Biopharma | IND-enabling |
| Bi-XDC with RPT | Coherent Biopharma | Early-stage |
| mRNA Anticancer Vaccine | Sunshine Biopharma | Preclinical Research |
| Biosimilar Bevacizumab | Organon (2) | Phase 3 |
| Biosimilar Pembrolizumab | Organon (2) | Phase 3 |
| BCL-2 Inhibitor Program | Vincerx Pharma | Preclinical |
| Not specified in provided content | 3Sbio | Various |
| Preclinical Projects | Zion Pharma | Preclinical |
| Attenukine Oncology Candidate | Teva | Phase 1 |
| XEMA Tumor Marker ELISA Kit | XEMA Group | Commercial |
| KRAS inhibitor | Risen Pharma Tech | Preclinical/Phase 1 |
| KEAP1 Activator Program | Vividion Therapeutics | Phase 1 |